PDL BioPharma is a leader in the discovery; development and marketing of innovative therapies for serious or life-threatening illnesses; commercially focused on the acute care; hospital setting. Our therapeutic emphasis is on the areas of hepatorenal syndrome; inflammation and autoimmune diseases; cardiovascular disorders and cancer . Our roots are steeped in breakthrough antibody humanization technologywhich enabled the development of some of the most innovative therapeutic advances of the past decadeincluding Synagis for respiratory syncytial virus (RSV); Herceptin for metastatic breast cancer; Avastin for metastatic colorectal cancer; Mylotarg for acute myelogenous leukemia; and Xolair for persistent asthma. In the nearly 20 years that weve been in business; weve established a strong financial foundation based on royalty revenues from licensing our technology to a variety of biotechnology and pharmaceutical partners. In recent years; weve shifted from a royalty-driven enterprise into a commercial biopharmaceutical company. Through acquisitions and strategic partnerships; weve gained a commercial sales force and several marketed products. Weve also expanded our development pipeline and focused our research capabilities; resulting in a strong pipeline of six innovative therapies in Phase 2 or Phase 3 development and a strategy to continue fueling that pipeline through both internal discovery and collaboration. Through these efforts; weve transformed our business and now were focused on becoming a sustainably profitable business enterprise.
Discover specific contacts and email addresses at PDL BioPharma, Inc..
Request a full profile of PDL BioPharma, Inc. with decision maker contacts and email address: